areisli

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update https://www.lysogene.com/wp-content/themes/crocal/images/empty/thumbnail.jpg 150 150 Lysogene Lysogene https://www.lysogene.com/wp-content/themes/crocal/images/empty/thumbnail.jpg September 25, 2020 September 25, 2020

Cash position of €23.8m as of 30 June 2020 strengthened by a €7.7m capital increase ledby OrbiMed and Sarepta, extending cash runway to Q4 2021

Lysogene annonce ses résultats semestriels 2020 et fait le point sur ses activités

Lysogene annonce ses résultats semestriels 2020 et fait le point sur ses activités https://www.lysogene.com/wp-content/themes/crocal/images/empty/thumbnail.jpg 150 150 Lysogene Lysogene https://www.lysogene.com/wp-content/themes/crocal/images/empty/thumbnail.jpg September 25, 2020 September 25, 2020

Trésorerie de 23,8 M€ au 30 juin 2020, renforcée par une augmentation de capital de 7,7 M€ auprès d’OrbiMed et Sarepta, portant la visibilité financière au T4 2021

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update

Lysogene annonce ses résultats semestriels 2020 et fait le point sur ses activités

Lysogene COVID-19 update

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

©2020 Lysogene. All rights reserved.

Get In Touch